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Voiding dysfunction due to detrusor underactivity or urethral sphincter dysfunction is a treatment
challenge for urologists. Recently, urologists have used botulinum toxin A (BoNT-A) injection into the
urethral sphincter to treat voiding dysfunction. This treatment has been found to decrease urethral
pressure and postvoid residual volume, and increase voiding efﬁciency in patients with neurogenic
detrusor sphincter dyssynergia, nonneurogenic dysfunctional voiding, and detrusor underactivity.
Although not all patients can achieve excellent therapeutic outcomes, patients with idiopathic detrusor
underactivity might have recovery of detrusor contractility after urethral sphincter BoNT-A injection.
However, urinary incontinence might be a de novo adverse event after treatment. Repeat urethral in-
jection is necessary to maintain therapeutic efﬁcacy. Patients should be fully informed of the limited
therapeutic efﬁcacy and possible adverse events prior to treatment. This article reviews recent studies of
urethral sphincter BoNT-A treatment for voiding dysfunction.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Voiding dysfunction may result from bladder outlet obstruction,
detrusor underactivity, or a poorly relaxed urethral sphincter dur-
ing micturition. Voiding dysfunction may be neurogenic or non-
neurogenic in origin, which causes difﬁculty in urination, a large
postvoid residual urine (PVR) volume, and upper urinary tract
deterioration. Treatment of voiding dysfunction with medication,
abdominal straining to void, clean intermittent catheterization
(CIC), or a cystostomymay help in some cases, but these techniques
are ineffective in many others. Botulinum toxin A (BoNT-A) has
been used for the treatment of lower urinary tract symptoms
(LUTS) since the late 1980s. Dykstra and Sidi [1] injected BoNT-A
into the external urethral sphincter of patients with spinal cord
injury (SCI) to induce chemical sphincterotomy and to lower
detrusor-sphincter dyssynergia.
BoNT-A has been used safely in the treatment of several types of
neurogenic spasticity including that in patients with SCI or multipleBuddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
lief Tzu Chi Foundation. Publishedsclerosis (MS) and detrusor sphincter dyssynergia. Schurch et al [2]
reported that 21 of 24 patients with SCI beneﬁted from BoNT-A
injection. In patients with dysfunctional voiding due to urethral
sphincter overactivity, nonbacterial prostatitis, and detrusor un-
deractivity, BoNT-A has been shown to have therapeutic effects in
improving voiding efﬁciency and recovering detrusor contractility
in some patients with few adverse effects [3,4]. Phelan et al [4]
found that after BoNT-A injection, 67% of patients were able to
void smoothly with the PVR decreased by 71% and voiding pressure
decreased by 38%.2. Mechanism of BoNT-A in voiding dysfunction
Botulinum neurotoxin (BoNT), produced by Clostridium botuli-
num, a gram-positive, rod-shaped anaerobic bacterium, was origi-
nally thought to only act by inhibiting acetylcholine (ACh) release at
the presynaptic cholinergic neuromuscular junction and has been
used effectively for different conditions with muscular hyper-
contraction [5,6]. There are seven immunologically distinct neu-
rotoxins designated as types A to G [7]. All serotypes of BoNT can
block transmission at neuromuscular junctions; however, only type
A BoNT (BoNT-A) has prolonged therapeutic effects. It is the most
extensively studied, mainly in models of neurotransmission in
striated muscle.by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Indications of botulinum toxin injection for lower urinary tract dysfunction.
Injection Disease Dose of Botox (U)
Bladder Neurogenic detrusor overactivity 200e300
Idiopathic detrusor overactivity 100e200
Interstitial cystitis 100e200
Overactive bladder or hypersensitive bladder 100
Low bladder compliance 200e300
Urethra Detrusor sphincter dyssynergia 100
Detrusor underactivity & nonrelaxing urethra 50e100
Prostate Benign prostatic hyperplasia 200e400
Chronic prostatitis 200
Pelvic ﬂoor Chronic pelvic pain syndrome 100e200
Poor relaxation of pelvic ﬂoor 100e200
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amino acids. Activation occurs when the single chain is cleaved by
an endogenous clostridial protease [5,8]. After the cleavage, a
dichain polypeptide is formed, which contains a 50-kDa light chain
and a 100-kDa heavy chain linked covalently by a weak disulﬁde
bond [8]. BoNT-A inhibits signal transmission at the neuromuscular
and neuroglandular junction through four discrete steps: (1)
binding of the toxin heavy chain to a speciﬁc nerve terminal re-
ceptor; (2) internalization of the toxin within the nerve terminal;
(3) translocation of the light-chain into the cytosol; and (4) cleaving
of synaptosome-associated protein 25 (SNAP-25) and inhibiting
signal transmission by disrupting the fusion of neurotransmitter-
containing vesicles with the neuronal wall [9]. Each botulinum
serotype cleaves a distinct protein site. BoNT-A cleaves SNAP-25,
and type B cleaves synaptobrevin [5,6].
BoNT-A administration has the same clinical effect on both
smooth and striated muscle. BoNT-A could reduce cholinergic
nerve-induced bladder activity as well as impair adenosine
triphosphate release in addition to ACh release from isolated
bladder tissue [10,11]. In a study of structural changes in detrusor
muscle, Haferkamp et al [12] observed no signiﬁcant changes in
muscle cell fascicles, intercellular collagen content, or muscle cell
degeneration when comparing biopsies taken prior to and
3 months after BoNT-A administration. Unlike that in striated
muscle, axonal sprouting in detrusor smooth muscle is limited
following BoNT-A administration.
3. Rationale for BoNT-A in the treatment of voiding
dysfunction
Voiding dysfunction might be caused by low detrusor contrac-
tility or high urethral sphincter resistance during voiding. Reduc-
tion of bladder outlet resistance could improve voiding efﬁciency in
patients with either detrusor underactivity or urethral sphincter
dysfunction. Injection of BoNT-A into the external sphincter blocks
ACh release at the neuromuscular junction and essentially achieves
chemical denervation of the external sphincter [1]. The goals of
urethral treatment are to lower the urethral pressure, or detrusor
leak point pressure, to below 40 cm of water and to promote
bladder emptying such that the upper urinary tract is protected
against the high bladder pressure. Based on previous clinical
studies, the clinical effects beginwithin 2e3 days and are reversible
as terminal nerve sprouting occurs 3e6 months later. In general, a
signiﬁcant decrease in the PVR and a signiﬁcant reduction in ure-
thral pressure could be observed [2,5]. However, appearance of de
novo stress urinary incontinence and exacerbation of preexisting
urinary incontinence due to sphincter denervation by BoNT-A have
been reported as adverse events [4,13].
BoNT-A could have effects on both efferent and afferent nerve
activity in the bladder wall, and might reduce the inﬂammatory
reaction in some cases of cystitis [5,6,10]. Based on its therapeutic
mechanism, BoNT-A can be used in the treatment of different lower
urinary tract diseases (Table 1). It can bind to the nerve endings
within muscles, blocking the release of ACh and perhaps other
neurotransmitters, to modulate muscle contraction and reduce the
sensitization of sensory nerve endings [10]. Selective injection
permits speciﬁc paralysis of the detrusor muscle while leaving
surrounding tissues and distant muscles unaffected [14]. Therapy
with BoNT-A would appear to not only help alleviate muscle
spasticity, but also promote antinociceptive properties and impact
on sensory feedback loops to relieve hyperalagesia or hypersensi-
tivity associated with a variety of LUTS. In BoNT-A treatment for
detrusor overactivity, there was an increase in capacity with a
reduction in urge incontinence episodes and symptoms of urgency
[14]. However, a more complete neuromuscular blockade of thedetrusor with larger doses of BoNT-A might result in impaired
voiding and acute urinary retention [5,14]. Most patients not
already performing CIC should be informed of the possibility of
long-term catheterization. In patients with low detrusor contrac-
tility or a large PVR at baseline, a lower dose of BoNT-A might be
given to avoid bladder paralysis and preserve voiding function [15].
4. Techniques for urethral sphincter injection of BoNT-A
Urethral sphincter BoNT-A injection can be performed in the
operating room under light intravenous general anesthesia (in
men) or in the outpatient department without anesthesia (in
women) [13]. Each vial of 100 U BoNT-A (Allergan, Irvine, CA, USA)
is reconstituted to 4 mL with normal saline, making the concen-
tration equivalent to 25 U/mL. The dose of BTX-A can be 50e100 U
for patients with detrusor underactivity who wish to void by
abdominal pressure after treatment, or 100 U for patients with
detrusor sphincter dyssynergia, dysfunctional voiding, or poor
relaxation of the urethral sphincter [1,2,13]. A total of 50 U or 100 U
of BoNT-A is injected into the urethral sphincter at the 3 o'clock, 6
o'clock, 9 o'clock, and 12 o'clock positions in approximately equal
aliquots using a cystoscopic injection instrument in men. Cystos-
copy is advised inwomen. The axis of the urethra is determined for
proper injection positions and BoNT-A is injected into the urethral
sphincter along the urethral lumen at the 3 o'clock, 6 o'clock, 9
o'clock, and 12 o'clock positions on the sides of urethral meatus
using a 23-gauge 1-mL syringe. If 50 U of BoNT-A is injected, 0.5 mL
is used for each injection. When 100 U of BoNT-A is injected,1 mL is
used for each injection.
During BoNT-A injection, patients are placed in the lithotomy
position. After sterilization and draping, the BoNT-A solution is
injected directly into the urethral sphincter under cystoscopic
guidance in men and periurethrally in women. For urethral in-
jections, it is essential to inject BoNT-A directly into the urethral
sphincter. Too much solution might cause leaking of BoNT-A
outside the urethral sphincter, resulting in an inadequate treat-
ment dose. The injection needle should not be inserted too deeply
to avoid injecting BoNT-A outside the sphincter muscle. With direct
visualization of the tight sphincter, the needle is injected 0.5 cm
deep at four or eight sites. The female urethra is about 3 cm long,
and the maximal diameter is at the middle portion of the urethra.
The injection needle should be inserted transcutaneously around
the urethral lumen in a longitudinal direction with the lumen to a
depth of 1.5 cm at four or eight sites. After the injections, a 14F Foley
indwelling catheter is inserted in male patients who have general
anesthesia, but a catheter is unnecessary in women.
The effect of BoNT-A usually appears about 2e3 days after in-
jection, and the maximum effects are reached in about 2 weeks.
Patients are instructed to void using the Crede maneuver or
abdominal straining. When difﬁcult urination persists, CIC is
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than 25% of the voided volume. Antibiotics may be given for 3 days
to prevent urinary tract infection to form urethral instrumentation.
Medications for reduction of urethral resistance may be dis-
continued if the patient can void efﬁciently after BoNT-A injections.
5. Urethral BoNT-A in treatment of neurogenic detrusor
sphincter dyssynergia in patients with SCI or MS
OnabotulinumtoxinA was ﬁrst applied in urethral sphincter in-
jection to treat detrusor sphincter dyssynergia in patients with SCI
who did not desire surgery or were unable to perform CIC [1,2].
After BoNT-A injection, the urethral sphincter showed decreased
urethral pressure, decreased PVR, and reduction in episodes of
autonomic dysreﬂexia [1,2,16]. Double-blind studies with BoNT-A
injection performed transperineally or transurethrally conﬁrmed
the validity and durability of this treatment [2,17]. A dose of 100 U
BoNT-A reduced the urethral resistance and achieved efﬁcient
voiding in patients with SCI and detrusor sphincter dyssynergia
[1,14,16]. A systemic review also indicated a 50% reduction in uri-
nary tract infections after urethral BoNT-A injections for detrusor
sphincter dyssynergia in SCI patients [18]. Overall, 60.6% of patients
reported satisfactory results after injection of BoNT-A 100 U with
signiﬁcant reductions in voiding detrusor pressure and PVR, and
increases in the maximal urinary ﬂow rate. However, the inconti-
nence grade might increase after urethral BoNT-A injection, espe-
cially in patients with detrusor underactivity and low bladder
compliance. Most urinary incontinence after BoNT-A injection oc-
curs during sleep. [19]. Therefore, this procedure should be per-
formed in well-chosen patients with their full consent.
6. BoNT-A urethral injection for treatment of nonneurogenic
voiding dysfunction
As urethral BoNT-A injection had been successfully used in the
treatment of detrusor sphincter dyssynergia in SCI patients, this
treatment was further applied to adults with nonneurogenic
voiding dysfunction [4,20]. Good therapeutic results were further
conﬁrmed by several small cohort studies with doses of 50 U and
100 U BoNT-A [4,19,21]. Other indications include voiding
dysfunction due to urethral overactivity, dysfunctional voiding,
idiopathic detrusor underactivity, detrusor areﬂexia caused by
cauda equina lesions, and peripheral neuropathy [5,13,22]. In some
patients with idiopathic detrusor underactivity, recovery of detru-
sor contractility was noted after urethral BoNT-A injections. Some
patients had long-term effects for more than 1 year without repeat
injection [23]. However, although urethral resistance is reduced by
BoNT-A injection, patients still need to use abdominal pressure to
empty their bladders. The main causes of failed BoNT-A injection
are very low abdominal straining pressure, a tight urethral
sphincter, psychological inhibition, and bladder neck obstruction
[24].
Injections of BoNT-A at 50 U (n ¼ 48) or 100 U (n ¼ 55) were
used in a large series of patients (n¼ 103) with voiding dysfunction.
Forty (39%) patients had excellent results, 47 (46%) patients had
signiﬁcant improvement, and 16 (15%) patients had treatment
failure [13]. Among the patients with excellent results, those with
detrusor underactivity due to cauda equina lesions (62.5%) or
idiopathic causes (61.5%) had the best results, whereas those with
detrusor sphincter dyssynergia (27.6%) had the worst. The overall
success ratewas 84.5% (range, 75e100%). Indwelling catheters were
removed or CIC was discontinued in 39 (87%) of the 45 patients
with urinary retention (Table 2). Analysis of the patients with
excellent or improved results showed that voiding pressure
decreased signiﬁcantly, as did maximal urethral closure pressureand PVR at 2 weeks or 4 weeks after treatment. The subjective
maximum effect was achieved within 1e2 weeks. The mean void-
ing pressure decreased by 31.8%, maximum ﬂow rate increased by
49.3%, PVR decreased by 60.8%, and maximal urethral closure
pressure decreased by 28.1%.
7. BoNT-A treatment of urethral sphincter pseudodyssynergia
in patients with cerebrovascular accidents or intracranial
lesions
Patients with neurogenic lesions and voiding dysfunction often
have mixed storage and voiding symptoms. Detrusor overactivity
and urethral sphincter pseudodyssynergia may develop during
recovery from cerebral vascular accident (CVA) or intracranial le-
sions, resulting in difﬁculty in urination, a large PVR, and recurrent
urinary tract infections. Patients who are ambulatory and wish to
urinate voluntarily without catheterization might prefer resump-
tion of voiding ability. Urethral sphincter injections of 100e200 U
BoNT-A in 4 mL divided in equal doses into four quadrants of the
urethral sphincter have been shown effective in patients with MS,
CVA, and SCI [5,20]. Patients with CVA and chronic urinary reten-
tion could also discontinue CIC after urethral injection of 100 U
BoNT-A [5,25].
In a prospective study, 21 patients with chronic CVA or intra-
cranial lesions and difﬁcult urination were enrolled to evaluate the
effectiveness of urethral injection of BoNT-A. Patients participating
in the study elected to receive either 100 U of BoNT-A (n ¼ 11) or
served as medically treated controls (n ¼ 10). An overall success
rate of 91% was noted in the study group. The voiding pressure
decreased (57.8 ± 35.2 cm vs. 33.8 ± 16.9 cm water, p ¼ 0.005) and
themaximum ﬂow rate increased (7.2 ± 5.9mL/s vs.10.3± 5.2mL/s,
p ¼ 0.005) signiﬁcantly. In the control group, four patients (40%)
had spontaneous voiding 6 months after medical treatment,
whereas six others remained unchanged, requiring an indwelling
Foley catheter (n ¼ 2) or CIC (n ¼ 4). The symptom score and the
quality of life index showed signiﬁcantly greater improvement in
the study group than in the control group. Urethral injection of
BoNT-A is effective and without adverse effects in the treatment of
patients with urethral sphincter pseudodyssynergia after CVA or
intractranial lesions.
Although urethral BoNT-A injection is effective in improving
voiding efﬁciency, incomplete emptying remains a problem and
mild stress urinary incontinence is another de novo issue after
treatment, especially in women with SCI or MS [5,19,20,26].
Therefore, if they have not been well informed prior to BoNT-A
injection, patients might not be satisﬁed with the therapeutic re-
sults of BoNT-A injection [19,27]. Large-scale randomized studies
are needed to assess the true therapeutic efﬁcacy and impact on
quality of life in those with neurogenic voiding dysfunctions.
8. Effectiveness of BoNT-A urethral injection in treatment of
voiding dysfunction after radical hysterectomy
After radical hysterectomy for cervical cancer, patients may have
difﬁcult urination owing to detrusor underactivity and a non-
relaxing urethral sphincter. One study evaluated the effectiveness
of urethral injection of BoNT-A in treating voiding dysfunction in
these patients [22]. Thirty patients with difﬁcult urination after
radical hysterectomy for cervical cancer received urethral injection
of 100 U of BoNT-A (n ¼ 20) or medical treatment as controls
(n ¼ 10). After urethral BoNT-A injections, eight patients had
excellent results (40%) and eight had improvement (40%) in the
study group. There were signiﬁcant improvements in both voiding
pressure (115.2 ± 63.7 mL vs. 90.2 ± 49.5 mL, p ¼ 0.025) and PVR
(330.9 ± 124.9 mL vs. 183.9 ± 183.4 mL, p ¼ 0.011) after treatment.
Table 2
Therapeutic efﬁcacy of urethral sphincter BoNT-A injection for neurogenic or nonneurogenic voiding dysfunction.
Disease Patients Excellent result Improved result Failure
DSD 29 8 (27.6) 15 (51.7) 6 (20.7)
Dysfunctional voiding 20 6 (30) 14 (70) 0
Nonrelaxing urethral sphincter 10 8 (42.1) 7 (36.8) 4 (21.1)
Cauda equine lesion 8 5 (62.5) 1 (12.5) 2 (25)
Peripheral neuropathy 14 5 (35.7) 6 (42.9) 3 (21.4)
Idiopathic detrusor underactivity 13 8 (61.5) 4 (30.8) 1 (7.7)
Totals 103 40 (38.8) 47 (45.7) 16 (15.5)
Data are presented as n (%).
Note. From “Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction,” by H.C. Kuo, 2003, J Urol, 170, p. 1908e12. Copyright 2003. American
Urological Association. Reproduced with permission.
BoNT-A ¼ botulinum toxin A; DSD ¼ detrusor sphincter dyssynergia.
H.-C. Kuo / Tzu Chi Medical Journal 28 (2016) 89e9392The obstructive symptom score decreased signiﬁcantly (17.5 ± 4.7
points vs. 5.7 ± 2.3 points, p ¼ 0.000), and the quality of life index
also improved (4.5 ± 2.7 points vs. 2.3 ± 2.3 points, p ¼ 0.000). The
success rate was 80% in the study group. There were no signiﬁcant
changes in obstructive symptom scores or the quality of life index
in the control group. The maximal effect appeared about 1 week
after treatment. The duration of the therapeutic effect ranged from
3 months to 9 months. Mild stress urinary incontinence and
nocturnal enuresis were noted in seven patients (35%). This study
has shown that urethral injection of BoNT-A can be effectively used
to treat patients with detrusor underactivity and nonrelaxing ure-
thral sphincter after radical hysterectomy with few adverse effects.
9. Effect of BoNT-A in treatment of voiding dysfunction due
to dysfunctional voiding
Nonneurogenic voiding dysfunction due to dysfunctional void-
ing is a therapeutic challenge for urologists. Dysregulated urethral
functionwith a spastic or nonrelaxing external urethral sphincter is
thought to be the possible cause of dysfunctional voiding, and re-
sults in voiding symptoms, a slow urinary ﬂow, large PVR, and
sometimes deterioration in upper urinary tract function. A large
PVR develops because patients do not have adequate urethral
sphincter relaxation during voiding, and CIC or an indwelling Foley
catheter is necessary to empty the bladder.
BoNT-A injection has been licensed for use in patients with
neurogenic detrusor overactivity or nonneurogenic overactive
bladder [28]. However, its use for voiding dysfunction remains an
off-label treatment. Nevertheless, BoNT-A injections to the lower
urinary tract have been widely applied in various types of voiding
dysfunction, including urethral sphincter injection for neurogenic
or nonneurogenic dysfunctional voiding [29]. In 1997, Steinhardt
et al [30] ﬁrst used urethral sphincter BoNT-A injection to treat a
neurologically normal child with refractory dysfunctional voiding.
The patient had no more urinary tract infections or incontinence
episodes after treatment. For pediatric dysfunctional voiding, ure-
thral sphincter injection with BoNT-A 50e100 U resulted in 90%
patients voiding without catheterization and with increased
maximum ﬂow rates and lower PVRs [30]. An increased dose of
200e300 U seems to increase the efﬁcacy without increased
morbidity [31]. BoNT-A injection can effectively improve the
voiding condition in neurologically normal children with urody-
namically proven dysfunctional voiding complicated by recurrent
urinary tract infections or a large PVR [32]. For adults with
dysfunctional voiding and poor relaxation of the urethral sphincter,
overall subjective successful results of 86.7% and 95.7% have been
reported, respectively, after urethral sphincter injection of
50e100 U BoNT-A [23]. Through the paralysis of the urethral
sphincter and reduction of urethral resistance, BoNT-A injection
therapy could facilitate bladder emptying, improve subjectivesymptoms and quality of life, and even reduce the frequency of CIC
[4,13].
10. Recovery of detrusor contractility in patients with
idiopathic detrusor underactivity after urethral BoNT-A
injection
Twenty-seven patients with idiopathic low detrusor contrac-
tility received urethral injections of BoNT-A. Thirteen (48%) patients
had recovery of detrusor contractility, deﬁned as an increase in
detrusor pressure and maximum ﬂow rate and reduced PVR [23].
These 13 patients had baseline data characterized by normal
bladder sensation during bladder ﬁlling combined with poor
relaxation or hyperactive urethral sphincter activity. By contrast,
patients without recovery of detrusor contractility had poor
bladder sensation and a nonrelaxing urethral sphincter. Patients
with low detrusor contractility combined with poorly relaxed or
hyperactive urethral sphincter activity had better results than those
with true detrusor underactivity. Five of the 13 patients with
detrusor contractility recovery had long-term effects without the
need for repeat urethral injection of BoNT-A for more than 1 year of
follow-up.
Patients with detrusor underactivity with normal bladder
sensation combined with poor relaxation or a hyperactive urethral
sphincter were signiﬁcantly more likely to recover normal detrusor
function. Neuromodulation of the hyperactive urethral sphincter by
urethral BoNT-A is the likely mechanism for this therapeutic effect.
Through inhibition of the afferent input of the urethral sphincter,
the inhibitory effect of the detrusor nucleus in the sacral cords may
be reduced and patients can resume spontaneous and efﬁcient
voiding.
11. Possible causes of treatment failure after urethral BoNT-A
injection
The possible causes of treatment failure included psychological
inhibition of voiding, low generation of abdominal pressure, non-
relaxing urethral sphincter obstruction, complete denervation of
the urethral sphincter, and bladder neck obstruction [24]. Identi-
ﬁcation of the underlying causes may indicate appropriate therapy.
Urethral hyperactivity in patients with detrusor sphincter dyssy-
nergia can be managed by repeat urethral injections of high doses
(100e200 U) of BoNT-A, whereas patients with nonneurogenic
dysfunctional voiding can be treated with lower doses (50e100 U).
In patients with detrusor underactivity and voiding dysfunction,
urethral sphincter BoNT-A may be tried if the bladder neck is open.
If videourodynamic study shows a tight bladder neck, patients
should be treated with transurethral incision of the bladder neck
ﬁrst. Urethral sphincter BoNT-A treatment will not be successful if
the bladder neck is not open in patients with detrusor
H.-C. Kuo / Tzu Chi Medical Journal 28 (2016) 89e93 93underactivity. Patients with complete denervation of the urethral
sphincter as demonstrated by electromyographic study should not
have these injections. The cost-effectiveness of BoNT-A treatment
should also be carefully considered.12. Conclusion
BoNTA urethral sphincter injection is effective in treatment of
voiding dysfunction due to neurogenic or nonneurogenic sphincter
dysfunction as well as detrusor underactivity refractory to con-
ventional medical treatment. Although not all patients can achieve
excellent therapeutic outcomes, patients with idiopathic detrusor
underactivity might have recovery of detrusor contractility after
urethral sphincter BoNT-A injection. However, urinary inconti-
nence might be a de novo adverse event. Patients who are planning
urethral sphincter BoNT-A injection for voiding dysfunction should
be fully informed of the limited therapeutic efﬁcacy and possible
adverse events prior to the treatment.References
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